{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009005","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.384124+00:00","generated_at":"2026-05-16T11:05:24.035847+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monte Rosa prices $300M public offering of common stock and pre-funded warrants","bullets":["Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.","Gross proceeds ~$300M; estimated net ~$281.6M after discounts and expenses.","Underwriters granted 30-day option to purchase up to 1,875,000 additional shares.","Proceeds to fund MRT-8102 for atherosclerotic cardiovascular disease, QuEEN platform development, and working capital.","Expects cash runway into 2029; closing expected on or about January 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009005","json":"https://secwatch.observer/filing/0001193125-26-009005.json","markdown":"https://secwatch.observer/filing/0001193125-26-009005.md","text":"https://secwatch.observer/filing/0001193125-26-009005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/0001193125-26-009005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/d36015d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:05:24.035847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa358c5996c7ec4d51605a9336968e91d70165b0","claim":"Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at $24.00 per share (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 11,125,000 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a public offering price of $24.00 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/0001193125-26-009005-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters"},{"label":"Value","value":"$24.00 per share"},{"label":"Effective","value":"2026-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}